Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore SARS-CoV-2 Sequencing Test Gets CE Mark

NEW YORK – Oxford Nanopore Technologies said on Friday that its LamPore SARS-CoV-2 sequencing test has obtained the CE mark for use with the GridIon platform.

The assay, which combines loop-mediated isotheral amplification (LAMP) with nanopore sequencing and can run on the GridIon and MinIon Mk1C platforms, targets the ORF1a, E, and N genes of the virus. Last month, researchers in the UK published a preprint of a validation study involving around 500 clinical samples, showing that the test is highly reproducible and has a sensitivity of 99.1 percent and a specificity of 99.6 percent.

Oxford Nanopore is rolling the LamPore test out globally, initially in the UK, Germany, Switzerland, and the United Arab Emirates, according to a company statement.

It is also pursuing regulatory approvals in other countries, including Emergency Use Authorization in the US and, in collaboration with G42, authorization in the United Arab Emirates.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.